Ignite Creation Date:
2025-12-24 @ 1:17 PM
Ignite Modification Date:
2025-12-30 @ 3:37 PM
Study NCT ID:
NCT05356195
Status:
RECRUITING
Last Update Posted:
2025-10-14
First Post:
2022-04-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
Sponsor:
Vertex Pharmaceuticals Incorporated
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-03
Start Date Type:
ACTUAL
Primary Completion Date:
2026-05-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-05-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-04-07
First Submit QC Date:
None
Study First Post Date:
2022-05-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-09
Last Update Post Date:
2025-10-14
Last Update Post Date Type:
ESTIMATED